ParkerWhite
Turning Medtech Innovation into Market Adoption

Medical technology companies are built around innovation. But creating a better technology and getting the market to adopt it are two very different challenges.

Today, commercialization requires more than convincing a physician that a product works. Medtech companies must establish value across an increasingly complex healthcare ecosystem. Clinicians evaluate outcomes and usability. Hospital executives consider economics and operational impact. Value analysis committees scrutinize evidence and cost. Supply chain teams assess standardization. Patients increasingly research and influence their own treatment decisions.

Helping companies navigate that complexity is ParkerWhite, a healthcare marketing and branding agency with nearly three decades of experience helping medical technology companies turn innovation into market adoption.

Rather than viewing marketing as a downstream function that begins when a product is ready to launch, ParkerWhite approaches it as an integral part of commercialization.

“Most of the companies we work with don’t have an innovation problem. They have an adoption problem,” says Keith White, Co- Founder and Chief Growth Officer of ParkerWhite. “The technology may be extraordinary, but the market still needs a compelling reason to change what it is doing today.”

That perspective shapes ParkerWhite’s approach.

The agency begins by identifying the barriers standing between an innovation and adoption. Through stakeholder research, competitive analysis, physician and executive interviews, buyer development, positioning and messaging architecture, ParkerWhite works to determine not simply what makes a technology different, but why that difference should matter to the people responsible for adopting, recommending, purchasing and using it.

This becomes particularly important in institutional healthcare, where the customer is increasingly a buying system rather than a single decision-maker.

Depending on the technology, adoption can involve physicians, nurses, executives, value analysis committees, procurement, finance, supply chain and reimbursement stakeholders. Each views value through a different lens.

ParkerWhite develops a single, differentiated market position and then translates that position into the clinical, economic, operational and human value required by each audience.

Once that strategic foundation is established, ParkerWhite connects brand to demand, carrying the same commercial story through product launches, digital experiences, HCP and patient marketing, sales enablement, content, SEO, paid media, CRM and demand generation.

The agency has applied this approach across organizations including FUJIFILM Sonosite, Orthofix, SeaSpine and Epitomee, working with companies ranging from established medical device manufacturers to emerging innovators introducing entirely new technologies and categories.

ParkerWhite also brings deep experience operating within the regulatory realities of healthcare marketing. The objective is not to make regulated communications more conservative, but to identify the strongest differentiated story that available clinical evidence can support.

Artificial intelligence is adding a new dimension to ParkerWhite’s commercialization approach.

Rather than using AI simply to produce more content faster, ParkerWhite is integrating it into research, competitive intelligence and strategic decision-making—combining nearly three decades of medtech experience with AI-enabled analysis to surface patterns, challenge assumptions and help clients make faster, betterinformed decisions about positioning, adoption and growth.

“Our job isn’t simply to make medical technology look good,” says White. “Our job is to make innovation understandable, credible and adoptable. When marketing does that, it becomes part of commercialization rather than something added at the end.”

As medical innovation accelerates and healthcare buying becomes more complex, ParkerWhite remains focused on the critical distance between creating a better solution and giving the market enough reason, evidence and confidence to choose it.